Transition From Pediatric to Adult Neurologic Care

Ann H. Tilton, MD, FAAN; Claudio Melo de Gusmao, MD Child Neurology p. 276-287 February 2018, Vol.24, No.1 doi: 10.1212/CON.0000000000000570
REVIEW ARTICLES
BROWSE ARTICLES
Article as PDF
-- Select an option --

PURPOSE OF REVIEW With advances in medical care, the number of youths surviving with medically complex conditions has been steadily increasing. Inadequate transition planning and execution can lead to gaps in care, unexpected emergency department visits, and an increase in health care costs and patient/caregiver anxiety. Many barriers that prevent adequate transition have been identified, including insufficient time or staff to provide transition services, inadequate reimbursement, resistance from patients and caregivers, and a dearth of accepting adult providers.

RECENT FINDINGS Transition is distinct from transfer of care. Transition is a planned multistage process, while transfer refers to a point in time where responsibility of care shifts from one provider to another. Key differences exist between the pediatric and adult models of care. A successful transition should empower the patient to understand and take responsibility in managing his or her condition; foster independent functioning to the extent that is possible; integrate educational, legal, and community resources in the care plan; and identify appropriate adult health care providers at the time of transfer. Different models have been proposed to streamline the transition process, with improvement in patients' knowledge of their condition, self-efficacy, and confidence.

SUMMARY Neurologists have a key role in supporting their patients in the transition to adulthood. This article reviews basic tenets and provides tools to assist in navigating the complex transition process. These tenets are intended to improve quality of care and decrease clinician burden and remain an active area of research.

Address correspondence to Dr Ann Tilton, Children’s Hospital of New Orleans, 200 Henry Clay Ave, Ste 3314, New Orleans, LA 70118, [email protected].

RELATIONSHIP DISCLOSURE: Dr Tilton serves on the board of directors of the American Academy of Neurology, on the editorial boards of the Journal of Child Neurology and Neurology, and as a consultant for Ipsen Biopharmaceuticals, Inc. Dr Tilton has received personal compensation for speaking engagements, and research/grant support from Ipsen Biopharmaceuticals, Inc, and receives patent royalties through her institution for botulinum toxin in the prevention and treatment of acne. Dr de Gusmao reports no disclosure.

UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Tilton and de Gusmao report no disclosure.

CONTINUUM AUDIO INTERVIEW AVAILABLE ONLINE

SUPPLEMENTAL DIGITAL CONTENT (SDC) AVAILABLE ONLINE

© 2018 American Academy of Neurology.